Tempus AI (NASDAQ:TEM) Stock Rating Lowered by Wall Street Zen

Tempus AI (NASDAQ:TEM) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday.

Several other analysts also recently commented on the company. Mizuho started coverage on Tempus AI in a research note on Thursday, February 19th. They set an “outperform” rating and a $100.00 price objective on the stock. JPMorgan Chase & Co. lowered their price target on Tempus AI from $80.00 to $60.00 and set a “neutral” rating for the company in a report on Wednesday, February 25th. Morgan Stanley lifted their price objective on Tempus AI from $80.00 to $85.00 and gave the company an “overweight” rating in a report on Monday, December 1st. Canaccord Genuity Group decreased their price objective on Tempus AI from $95.00 to $80.00 and set a “buy” rating for the company in a research report on Monday, December 22nd. Finally, Stifel Nicolaus set a $60.00 target price on shares of Tempus AI in a report on Wednesday. Eight analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Tempus AI currently has a consensus rating of “Moderate Buy” and a consensus price target of $79.31.

Tempus AI Trading Down 3.9%

TEM opened at $53.25 on Friday. The firm’s fifty day moving average is $61.34 and its two-hundred day moving average is $73.35. The firm has a market cap of $9.47 billion, a PE ratio of -37.77 and a beta of 5.29. Tempus AI has a twelve month low of $36.22 and a twelve month high of $104.32. The company has a debt-to-equity ratio of 2.52, a quick ratio of 3.00 and a current ratio of 3.13.

Insider Buying and Selling at Tempus AI

In related news, CFO James William Rogers sold 19,966 shares of Tempus AI stock in a transaction that occurred on Thursday, December 11th. The stock was sold at an average price of $73.20, for a total value of $1,461,511.20. Following the sale, the chief financial officer owned 111,250 shares of the company’s stock, valued at approximately $8,143,500. This trade represents a 15.22% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Eric P. Lefkofsky sold 166,250 shares of the company’s stock in a transaction that occurred on Thursday, December 18th. The stock was sold at an average price of $63.99, for a total value of $10,638,337.50. Following the transaction, the chief executive officer directly owned 8,974,783 shares of the company’s stock, valued at approximately $574,296,364.17. This trade represents a 1.82% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 590,109 shares of company stock valued at $37,056,566 in the last 90 days. 26.27% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Tempus AI

Several hedge funds and other institutional investors have recently made changes to their positions in TEM. Cranbrook Wealth Management LLC bought a new stake in Tempus AI during the third quarter worth $25,000. JPL Wealth Management LLC acquired a new position in shares of Tempus AI during the 3rd quarter worth about $26,000. GAMMA Investing LLC bought a new stake in shares of Tempus AI in the 3rd quarter valued at about $28,000. Allworth Financial LP lifted its stake in Tempus AI by 5,000.0% in the 2nd quarter. Allworth Financial LP now owns 459 shares of the company’s stock valued at $29,000 after purchasing an additional 450 shares during the last quarter. Finally, Los Angeles Capital Management LLC bought a new position in Tempus AI during the fourth quarter worth about $27,000. 24.22% of the stock is owned by institutional investors.

Tempus AI News Summary

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Beat-and-raise fundamentals — Tempus reported robust Q4 and full‑year 2025 results (strong revenue growth, narrower net loss, positive adjusted EBITDA progression) and issued 2026 guidance that targets revenue growth and a first full‑year adjusted EBITDA inflection, supporting a fundamental recovery case. Why Tempus AI (TEM) Is Down 7.5% After 2025 Results
• Positive Sentiment: Product & commercial catalysts — Launch of an HRD‑RNA oncology algorithm and a partnership with Median Technologies to expand lung cancer screening distribution broaden Tempus’s diagnostic pipeline and addressable market if adoption scales. Tempus AI Deepens Precision Oncology Role With New HRD And Lung Tools
• Positive Sentiment: Institutional support and rebound narrative — Several outlets highlight heavy institutional buying, improving unit economics and analyst upside scenarios, which could limit downside and set up a technical rebound if execution continues. Tempus AI Sold Off After a Beat—But the Rebound Case Is Building
• Neutral Sentiment: Investor event calendar — Management will present at the Morgan Stanley TMT conference (March 3); the fireside chat could provide additional color but is not a guaranteed catalyst. Tempus to Participate in the Morgan Stanley Technology, Media & Telecom Conference
• Neutral Sentiment: Valuation updates — Some fair‑value and price‑target revisions trimmed upside modestly; analysts still show a range of bullish and cautious views, leaving the story sensitive to near‑term execution. How The Tempus AI (TEM) Investment Story Is Evolving With New Data And Valuation Views
• Negative Sentiment: Analyst downgrades and price‑target cuts — Recent analyst actions (including a notable downgrade reported 2/27 and several target cuts in the prior 24 hours) have intensified selling pressure and weakened sentiment despite the beat. Tempus AI (NASDAQ:TEM) Shares Down 7.4% After Analyst Downgrade
• Negative Sentiment: ESOP shelf registration and dilution risk — Tempus filed a US$343.38M ESOP‑related shelf registration; potential future share issuance tied to employee plans can pressure the stock if investors fear dilution. Why Tempus AI (TEM) Is Down 7.5% After 2025 Results
• Negative Sentiment: Execution, debt and market risk — High leverage, a volatile post‑IPO trading history, elevated beta and lingering execution/valuation concerns make the stock susceptible to outsized moves on negative headlines. Is It Time To Reassess Tempus AI (TEM) After Recent Share Price Weakness?

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.